Toll-like receptors: a target for many therapeutic applications

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2008
  • Initiating Organization: Top Industry Pharma
  • Initiator Type: Nonprofit foundation
  • No disease focus
  • Location: Europe


The broad interest for the role of the toll-like receptor (TLR) protein family has led to TI Pharma’s largest project, in which scientists from many different disciplines participate. Some work has been done on the development of tools that can modulate the function of TLRs. For instance, probiotics are being selected and small molecules are being generated that specifically affect TLR activity. Also, the possibilities for improvement of vaccination strategies using TLRs are being explored. Other researchers investigate the role of TLRs in specific disease areas such as cancer and cardiovascular and autoimmune disease. The knowledge obtained through this type of basic research together with the tools developed to interfere in TLR functioning will provide insight into the possibilities for further drug development based on TLR signaling.


The consortium’s goal is to identify and make TLR modulators and develop potentially relevant therapeutic applications

Consortium History

The project duration was March 2008 to March 2012.

Sponsors & Partners


Danone Research

ISA Pharmaceuticals

Leiden University

Leiden University Medical Center

Maastricht University

Radboud University Medical Center


University Medical Center Utrecht

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.